tbuckley/cabot-search huggingface dataset:
Contribution of revision amputation vs replantation for certain digits to functional outcomes after traumatic digit amputations: A comparative study based on multicenter prospective cohort
Authors: Hongyi Zhu, Jianli Wang, Tao Gao, Maoyuan Tian, Lei Xia, Qianying Cai, Changqing Zhang, Yuben Xu, Xianyou Zheng
Journal: International Journal of Surgery (2021)

Traumatic digit amputations can result in significant impairment. Optimal surgical treatment is unclear for certain digits in various amputation patterns. Our aim was to compare the contribution of revision amputation vs replantation for each particular digit to functional outcomes.Prospective cohort study at three tertiary hospitals was conducted in China. Eligible participants were 3192 patients with traumatic digit amputations enrolled from January 1, 2014, to January 1, 2018. The primary outcome was Michigan Hand Outcomes Questionnaire (MHQ) scores 2 years after initial surgery. Secondary outcome was score on the Disabilities of the Arm, Shoulder, and Hand (DASH).Of 3192 enrolled patients, 2890 completed the study. Main-effect linear regression showed that participants with replantation of thumb, index, long, and ring (proximal to the proximal interphalangeal [PIP] joint) fingers had significantly better MHQ scores compared to participants with the corresponding finger revision amputation. DASH results were comparable. Finger-finger interaction analyses conducted with multifactor dimensionality reduction (MDR) revealed that the small finger and ring finger had the smallest and greatest interactions with other fingers, respectively. After stratification by amputation level of thumb, index finger, or long finger, linear regression showed that replantation of the ring finger distal to the PIP joint resulted in better MHQ and DASH when the thumb or long finger was also traumatically amputated proximal to the IP/PIP joint.Replantation of the thumb, index, long, and ring (proximal to PIP joint) fingers is preferable to revision amputation, regardless of amputation pattern. Replantation of the ring finger amputated distal to PIP was beneficial only when the thumb or long finger was amputated proximal to IP/PIP joint. Replantation or revision amputation of the small finger was indistinguishable in terms of functional outcome. Future investigations and clinical decisions should take into account the role of finger-finger interactions.
Iatrogenic Delivery for Suspected Fetal Growth Restriction and Childhood School Outcomes
Authors: Gordon C. S. Smith
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 11419: Outcomes of Transcatheter Aortic Valve Replacement in Patients with High Comorbidity versus Low Comorbidity Burden
Authors: Muddasir Ashraf, Viviana Zlochiver, Ryan Carnahan, M. Fuad Jan
Journal: Circulation (2021)

Introduction: Transcatheter aortic valve replacement (TAVR)’s on-par performance with surgical aortic valve replacement in clinical trials has led to its successful adoption in patients with high and low mortality risk. Here we evaluate if a correlation exists between comorbidity burden and in-hospital mortality (IHM) in TAVR patients and examine the factors associated with increased IHM. Methods: Using the National Inpatient Sample database, 148,315 adult patients who underwent TAVR from 2016 through 2018 were included in the study. The Elixhauser Comorbidity Index 2020 was used to identify comorbidities. All comorbidities were weighted equally. Patients with &lt;3 comorbidities were assigned to the low comorbidity group (LCG) and those with ≥3 comorbidities to the high comorbidity group (HCG). The primary outcome of interest was IHM in the HCG versus the LCG. Secondary outcomes were average length of stay (LOS) and average hospital charges. Results: The overall IHM rate in our sample was 1.52%. Unadjusted and adjusted IHM odds were not different between groups (unadjusted odds ratio=1.024, P=0.7994; adjusted odds ratio=1.022, P=0.8225). Female sex, non-elective admission for TAVR, and transapical access were found to be independent predictors of IHM when adjusted for other factors (Table). The adjusted average LOS was significantly higher in the HCG than the LCG (3.07 vs. 2.7 days, P&lt;0.0001). The adjusted average total hospital charges billed and average actual cost of hospital services were significantly higher in the HCG than the LCG (213,507 vs 208,019 USD, P=0.0032 and 55,284 vs 54,278 USD, P=0.0078; respectively). Conclusion: In-hospital mortality in TAVR patients is not significantly correlated with comorbidity burden. Female sex and procedural characteristics like transapical access and non-electiveness are more important in determining IHM. Resource utilization is higher in the HCG than the LCG.
Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study
Authors: Nathan H. Fowler, Michael Dickinson, Monalisa Ghosh, Andy Chen, Charalambos Andreadis, Ranjan Tiwari, Aisha Masood, Roberto Ramos, Vamsi Bollu, Etienne Jousseaume, Catherine Thieblemont, Martin H. Dreyling, Stephen J. Schuster
Journal: Blood (2021)
Abstract 10020: Worse Outcomes of Out-of-Hospital Cardiac Arrest in COVID-19 versus Non-COVID-19: A Systematic Review and Meta Analysis
Authors: Dr Dyutima, Sandeep Singh, Zaymis D Castillo, Christiana A Igbenabor, Lorannys Y Sanchez, Maria J Rueda, Confesora Valdez, Mirian Galan, Violeta Spasova, Rupak Desai
Journal: Circulation (2021)

Introduction: A surge in incidence of out-of-hospital cardiac arrest (OHCA) has been reported during COVID-19 outbreak in certain countries. However, limited data exists on a comparison of outcomes among COVID-19 positive OHCA patients vs. non- COVID-19 OHCA patients. Therefore, we aimed to perform a meta-analysis comparing characteristics and outcome of COVID-19 OHCA vs COVID-19 negative OHCA patients. Methods: We reviewed PubMed/Medline, SCOPUS, and EMBASE until April 2021 using relevant keywords COVID-19, SARS-CoV-2, “out of hospital cardiac arrest” or OHCA to identify studies that included outcomes data on OHCA with COVID-19 positive and negative status. Random-effects models were obtained to perform a meta-analysis. I 2 statistics was used for heterogeneity. Results: Of 5789 OHCA patients included from 6 studies, patients who were COVID-19 positive comprised of 61.46% males while COVID-19 negative patients included 63.37% of males (p=0.2). COVID-19 OHCA patients were younger (Mean±SD, 68.94±17.93 vs 70.23±17.93, p=0.03) compared to COVID-19 negative patients. Incidence of OHCA at home/private address was higher (OR=1.92, 95%CI:1.52-2.43), while shockable rhythm (OR=0.34, 95%-CI:0.24-0.46) and use of AED (OR=0.77, 95%CI 0.61-0.97) were less frequently noted in COVID-19 patients (p&lt;0.0001). As shown in Fig. 1 , return of spontaneous circulation did not differ significantly (OR=1.01, 95%CI:0.85-1.20, p&lt;0.92); however, survival to admission (OR=0.64, 95%CI:0.48-0.86, p&lt;0.01), and survival to discharge (OR=0.28, 95%CI:0.13-0.59, p&lt;0.01) were significantly lower in COVID-19 OHCA admissions compared to non-COVID-19 OHCA admissions. Conclusions: This meta-analysis demonstrated that the SARS-CoV-2 infection in OHCA patients was associated with poorer outcomes as compared to COVID-19 negative OHCA admissions. Future studies are warranted to assess long-term residual effects of COVID-19 on OHCA risk and outcomes.
A Simplified Novel Prognostic Score to Predict Early Mortality and Disease Progression in Patients with Aggressive Adult T-Cell Leukemia/Lymphoma
Authors: Bryan Valcarcel, Denisse Castro, Daniel J Enriquez, Camila Peña, Henry Idrobo, Lorena Fiad, Maria Prates, Sally Rose Paredes, Marialejandra Alejandra Torres Viera, Guilherme Fleury Perini, Jorge J. Castillo, Luis Villela, Brady E Beltran, Juan Carlos Ramos, Luis Malpica-Castillo
Journal: Blood (2021)
Abstract 10901: Association of Fried's Frailty Score and Sarcopenia with Outcomes After Left Ventricular Assist Device Implantation
Authors: Gourisree Dharmavaram, Andrew Lin, Gemmy Hannsun, Vuong Nguyen, Michelle Sirignano, Maggie Mendenhall, Eric D Adler, Victor Pretorius, Hao Tran
Journal: Circulation (2021)

Introduction: Measures of frailty are predictive of morbidity and mortality in patients with left ventricular assist device (LVAD) placement. While Fried’s Frailty Assessment (FFA) is well-validated, sarcopenia has emerged as a powerful predictor. The additive value of sarcopenia to existing frailty assessments and its association with outcomes in patients undergoing LVAD implantation is not well-characterized. Hypothesis: We assessed the hypothesis that sarcopenia in addition to FFA improves the assessment of frailty and that patients identified as frail may experience worse outcomes after LVAD implantation. Methods: We evaluated 34 patients who underwent LVAD implantation at our medical center between January 2018 and December 2020. Perioperative FFA score ≥ 3 was defined as frail. Skeletal muscle indices were measured using perioperative computed tomography imaging of the psoas and pectoralis major and minor muscles areas. Sarcopenia was defined per the lowest skeletal muscle tertile with total psoas area index ≤4.45 and pectoralis muscle index ≤4.50. Results: Of the 34 patients who had LVAD placement, 12 received HeartWare HVAD and 22 received HeartMate III. Five patients met criteria for frailty based on FFA. When combined with frailty based on sarcopenia, 13 additional patients met criteria. There were no differences in age (57 vs 54.5 years, p = 0.49) or gender (89% vs 100% male, p = 0.62) between the frail and non-frail groups. On Kaplan-Meier analysis, the frail group had significantly higher rates of composite outcome of 30-day readmission and all-cause mortality (log-rank p = 0.027), (Figure 1). There was no difference in rates of transplantation. Conclusions: In conclusion, FFA is a commonly used tool for assessing frailty in patients with heart failure. The addition of sarcopenia assessment allows for higher sensitivity in identifying patients with frailty who are at risk for poor outcomes. Larger studies are needed to validate these findings.
Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action
Authors: Jorge Alvar, Margriet den Boer, Daniel Argaw Dagne
Journal: The Lancet Global Health (2021)

East Africa is the world region most affected by visceral leishmaniasis, accounting for 45% of cases globally that were reported to WHO in 2018, with an annual incidence that is only slightly decreasing. Unlike southeast Asia, east Africa does not have a regional approach to achieving elimination of visceral leishmaniasis as a public health problem. The goal of the WHO 2021-30 Neglected Tropical Diseases road map is to reduce mortality caused by the disease to less than 1%. To achieve this goal in east Africa, it will be necessary to roll out diagnosis and treatment at the primary health-care level and implement evidence-based personal protection methods and measures to reduce human-vector contact. Investment and collaboration to develop the necessary tools are scarce. In this Health Policy paper, we propose a strategic framework for a coordinated regional approach in east Africa for the elimination of visceral leishmaniasis as a public health problem.
Trends in Use and Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Racial/Ethnic Minorities
Authors: Nandita Khera, Theresa E. Hahn, Ruta Brazauskas, Benjamin Jacobs, Leslie E. Lehmann, Hashmi Shahrukh, William A. Wood, Sikander Ailawadhi, Wael Saber
Journal: Blood (2021)
Introducing a Novel Biophysical Platelet Function Panel to Investigate Disorders of Primary Hemostasis and Bleeding of Unknown Cause
Authors: Sally Azer, Oluwamayokun Oshinowo, Meredith E. Fay, Yumiko Sakurai, Yongzhi Qiu, Carolyn M. Bennett, Shannon Meeks, Megan C. Brown, David R. Myers, Wilbur A. Lam
Journal: Blood (2021)
Abstract 9413: Quality Improvement for Improving Awareness of Cardiac Amyloidosis Among Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement (TAVR)
Authors: Dae Hyun Lee, Arjun Khadilkar, Rosalind Wheeler, jennifer Bishop, Bibhu D Mohanty, FADI MATAR, Hiram Bezerra, Guilherme H Oliveira, Joel Fernandez
Journal: Circulation (2021)

Introduction: Transthyretin cardiac amyloidosis (ATTR-CM) is an important comorbidity associated with aortic stenosis. Multiple studies have shown that the prevalence of ATTR-CM in severe AS is 15-20%. Concomitant AS and ATTR-CM confers worse outcomes than lone AS. Hypothesis: The purpose of this quality improvement project is to raise awareness of ATTR-CM in patients TAVR amongst the provider and patients. Methods: We retrospectively reviewed TAVR cases performed at our institution in 2019 (Total cases 87). We interrogated the presence of predefined high-risk features for ATTR-CM based on prior literature and guidelines. We subsequently contacted the identified subjects to discuss our suspicion of ATTR-CM and offered clinical referral to a cardiac amyloid specialist. Results: Of the total of 87 patients who underwent TAVR in 2019, 12 patients were deceased at time of chart review. We reviewed 75 patient medical records, of which 50 patients (66.7%) had high-risk features of ATTR-CM. Total of 19 patients (38%) agreed to being referred to a cardiac amyloid specialist. In addition, 7 more patients were found to be deceased on phone call (total 19 patients deceased), 18 patients could not be reached, and 6 patients declined referral. Conclusions: Comprehensive risk assessment approach in patients with severe AS may disclose otherwise unsuspected ATTR-CM and allow earlier diagnosis and treatment. These findings served as the basis for implementation of a prospective screening process for ATTR-CM utilizing pyrophosphate nuclear scanning in select patients referred for TAVR in our institution.
Prognostic Impact of <i>NPM1</i> and <i>FLT3</i> Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance
Authors: Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes
Journal: Blood (2021)
Risk of Infection Associated With Administration of Intravenous Iron
Authors: Akshay A. Shah, Killian Donovan, Claire Seeley, Edward A. Dickson, Antony J. R. Palmer, Carolyn Doree, Susan Brunskill, Jack Reid, Austin G. Acheson, Anita Sugavanam, Edward Litton, Simon J. Stanworth
Journal: JAMA Network Open (2021)

Importance Intravenous iron is recommended by many clinical guidelines based largely on its effectiveness in reducing anemia. However, the association with important safety outcomes, such as infection, remains uncertain. Objective To examine the risk of infection associated with intravenous iron compared with oral iron or no iron. Data Sources Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for randomized clinical trials (RCTs) from 1966 to January 31, 2021. Ongoing trials were sought from ClinicalTrials.gov, CENTRAL, and the World Health Organization International Clinical Trials Search Registry Platform. Study Selection Pairs of reviewers identified RCTs that compared intravenous iron with oral iron or no iron across all patient populations, excluding healthy volunteers. Nonrandomized studies published since January 1, 2007, were also included. A total of 312 full-text articles were assessed for eligibility. Data Extraction and Synthesis Data extraction and risk of bias assessments were performed according to the Preferred Reporting Items of Systematic Reviews and Meta-analyses (PRISMA) and Cochrane recommendations, and the quality of evidence was assessed using the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) approach. Two reviewers extracted data independently. A random-effects model was used to synthesize data from RCTs. A narrative synthesis was performed to characterize the reporting of infection. Main Outcomes and Measures The primary outcome was risk of infection. Secondary outcomes included mortality, hospital length of stay, and changes in hemoglobin and red blood cell transfusion requirements. Measures of association were reported as risk ratios (RRs) or mean differences. Results A total of 154 RCTs (32 762 participants) were included in the main analysis. Intravenous iron was associated with an increased risk of infection when compared with oral iron or no iron (RR, 1.16; 95% CI, 1.03-1.29; I 2 = 36%; moderate certainty of evidence). Intravenous iron also was associated with an increase in hemoglobin (mean difference, 0.57 g/dL; 95% CI, 0.50-0.64 g/dL; I 2 = 94%) and a reduction in the risk of requiring a red blood cell transfusion (RR, 0.83; 95% CI, 0.76-0.89; I 2 = 15%) when compared with oral iron or no iron. There was no evidence of an effect on mortality or hospital length of stay. Conclusions and Relevance In this large systematic review and meta-analysis, intravenous iron was associated with an increased risk of infection. Well-designed studies, using standardized definitions of infection, are required to understand the balance between this risk and the potential benefits.
Significant Improvements in Survival for Patients with t(6;9)(p23;q34)/<i>DEK-NUP214</i> in Contemporary Trials with Intensification of Therapy: A Report from the Children's Oncology Group
Authors: Katherine Tarlock, Todd A. Alonzo, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Betsy A Hirsch, Beverly Lange, William G. Woods, Todd M. Cooper, Alan S. Gamis, Jessica A. Pollard, Richard Aplenc, Anders E. Kolb, Soheil Meshinchi
Journal: Blood (2021)
Vaccine Efficacy after Rituximab Exposure: First Interim Analysis of Virtue Project on Behalf of West Midlands Research Consortium, UK
Authors: Adrian M Shields, Srinivasan Venkatachalam, Shankara Paneesha, Mark Ford, Tom Sheeran, Melanie Kelly, Farheen Karim, Iman Qureshi, Beena Salhan, Neelakshi DeSilva, Jacqueline Stones, Sophie Lee, Jahanzeb Khawaja, Praveen Kumar Kaudlay, Richard Whitmill, Ghulam Nabikakepoto, Sian E Faustini, Alex G Richter, Mark T Drayson, Supratik Basu
Journal: Blood (2021)
Transcriptional Reprogramming of Super-Enhancer Associated Oncogenes Following Inhibition of Cyclin-Dependent Kinase-9 (CDK9) in Aggressive Non-Hodgkin Lymphoma (NHL)
Authors: Elana Thieme, Duanchen Sun, Geeta G Sharma, Nur Bruss, Tingting Liu, Daniel J Coleman, Zheng Xia, Alexey V. Danilov
Journal: Blood (2021)
Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome
Authors: Melissa A. Hopper, Kerstin Wenzl, Keenan T. Hartert, Jordan E. Krull, Joseph P. Novak, Michelle K. Manske, MaKayla R. Serres, Vivekananda Sarangi, Melissa C. Larson, Matthew J. Maurer, Jonas Paludo, Ellen D. McPhail, Thomas M. Habermann, Brian K. Link, Lisa M. Rimsza, Stephen M. Ansell, James R. Cerhan, Dragan Jevremovic, Anne J. Novak
Journal: Blood (2021)
Average Lifetime Hemoglobin Concentration Improves Prediction of Cognitive Outcomes in Pediatric Patients with Sickle Cell Anemia
Authors: Anna M Hood, Hanne Stotesbury, Simisola Fadahunsi-Oduyemi, Jamie M Kawadler, Melanie Koelbel, Satwinder Sahota, Subarna Chakravorty, Olu Wilkey, Fenella Jane Kirkham, Joanna Howard, Baba PD Inusa
Journal: Blood (2021)
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome
Authors: Matthew S. Davids, Kerry A. Rogers, Svitlana Tyekucheva, Zixu Wang, Samantha Pazienza, Sarah K. Renner, Josie Montegaard, Udochukwu Ihuoma, Timothy Z. Lehmberg, Erin M. Parry, Catherine J. Wu, Caron A. Jacobson, David C. Fisher, Philip A. Thompson, Jennifer R. Brown
Journal: Blood (2021)
Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status — Oregon and Washington, July 4–September 25, 2021
Authors: Allison L. Naleway, Holly C. Groom, Phil M. Crawford, S. Bianca Salas, Michelle L. Henninger, Judy L. Donald, Ning Smith, Mark G. Thompson, Lenee H. Blanton, Catherine H. Bozio, Eduardo Azziz-Baumgartner
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Population-based rates of infection with SARS-CoV-2 (the virus that causes COVID-19) and related health care utilization help determine estimates of COVID-19 vaccine effectiveness and averted illnesses, especially since the SARS-CoV-2 B.1.617.2 (Delta) variant began circulating in June 2021. Among members aged ≥12 years of a large integrated health care delivery system in Oregon and Washington, incidence of laboratory-confirmed SARS-CoV-2 infection, emergency department (ED) visits, and hospitalizations were calculated by COVID-19 vaccination status, vaccine product, age, race, and ethnicity. Infection after full vaccination was defined as a positive SARS-CoV-2 molecular test result ≥14 days after completion of an authorized COVID-19 vaccination series.* During the July-September 2021 surveillance period, SARS-CoV-2 infection occurred among 4,146 of 137,616 unvaccinated persons (30.1 per 1,000 persons) and 3,009 of 344,848 fully vaccinated persons (8.7 per 1,000). Incidence was higher among unvaccinated persons than among vaccinated persons across all demographic strata. Unvaccinated persons with SARS-CoV-2 infection were more than twice as likely to receive ED care (18.5%) or to be hospitalized (9.0%) than were vaccinated persons with COVID-19 (8.1% and 3.9%, respectively). The crude mortality rate was also higher among unvaccinated patients (0.43 per 1,000) than in fully vaccinated patients (0.06 per 1,000). These data support CDC recommendations for COVID-19 vaccination, including additional and booster doses, to protect individual persons and communities against COVID-19, including illness and hospitalization caused by the Delta variant (1).
CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program
Authors: Paola Minetto, Fabio Guolo, Luana Fianchi, Marino Clavio, Michele Gottardi, Mauro Endri, Sara Galimberti, Giuliana Rizzuto, Margherita Sciumé, Michela Rondoni, Giambattista Bertani, Michelina Dargenio, Atto Billio, Barbara Scappini, Patrizia Zappasodi, Anna Maria Scattolin, Francesco Grimaldi, Giuseppe Pietrantuono, Pellegrino Musto, Cerrano Marco, Stefano D'Ardia, Ernesta Audisio, Alessandro Cignetti, Crescenza Pasciolla, Francesca Pavesi, Anna Candoni, Carmela Gurrieri, Monica Morselli, Caterina Alati, Nicola S Fracchiolla, Giovanni Rossi, Manuela Caizzi, Fabrizio Carnevale Schianca, Michele Cea, Agostino Tafuri, Giuseppe Rossi, Felicetto Ferrara, Livio Pagano, Roberto Massimo Lemoli
Journal: Blood (2021)